At Access InVivo, we’re passionate about improving global health by ensuring patients have access to life-changing innovations. Our mission is to help companies bring medicines to patients faster knowing that access is fully aligned with commercial success. Our work is supported by insights from the most distinguished set of access leaders ever assembled by a consultancy, each recognised as a thought-leader in their fields. Our advice is unique in that it is driven by extensive real-world experience in access decision-making, medicines development and commercialisation.
Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates
The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.
We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.
Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.
Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.
As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.
Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. Astex is developing a proprietary pipeline of novel therapies and has multiple partnered products in development under collaborations with leading pharmaceutical companies. Astex is a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., based in Tokyo, Japan.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
Aurum Biosciences Ltd is a UK based clinical stage biopharmaceutical company developing novel oxygen carriers for use as therapeutics and diagnostics, initially for Acute Ischaemic Stroke (AIS) and Inflammation Imaging. Follow-on indications include heart disease, cardiac arrest, oncology, spinal cord injury (SCI), and traumatic brain injury (TBI).
Barrington James are a global staffing and resourcing organisation who specialise in placing niche consultants of all levels in the Biotech and Pharmaceutical industry. We offer both short and long term solutions and can provide ad-hoc consultancy support as required. Our offices in Europe, USA and APAC means that we can provide a truly global solution and experience in a market you may not know.
All of our team are dedicated market specialists with unrivalled candidate networks and will be on hand in Hamburg to discuss any assistance you may need to aid you getting your product to market. We have proven experience in knowing the difference between working for a big pharma and a new start-up Biotech and will ensure that the people you hire truly understand your business and what you need to succeed.
Our breakthrough technology combines synthetic and stem cell biology, offering limitless possibilities. Enabling a new generation of cell therapies, providing the best human cells for research and drug discovery, and allowing the control of advanced synthetic biology circuits for biomanufacturing.
Centauri Therapeutics is an immunotherapy company currently focused on infectious diseases and oncology. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.
Centrix Pharma Solutions is a UK-based, development-focused CDMO specialising in early-stage drug product development and clinical trial manufacturing for orally delivered small molecules.
Built on the heritage of Custom Pharma Services (established in 1979), Centrix was created to support the most critical stages of drug development. guiding innovative biotech companies from concept to clinic with confidence. Our approach is rooted in deep pharmaceutical science, patient-centric design, and proactive risk management, ensuring drug products are designed right from the start.
We work as a genuine partner to our clients, combining formulation development, analytical strategy, and GMP clinical manufacturing within an integrated, agile model. By aligning product and patient requirements early, we help reduce rework, control timelines, and de-risk progression into first-in-human and later-phase clinical studies.
Centrix is trusted by early-stage and virtual biotech companies seeking flexibility, transparency, and direct access to experienced scientists. With a focus on collaboration and scientific integrity, we don’t just deliver services. we help turn promising molecules into patient-ready medicines.
By mining the genome using our bioinformatics platform we discover and re-purpose natural gene regulatory elements, creating customised gene expression systems to: Improve human health, Engineer biology and Enable traits discovery.
